TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14768515

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (maintained with isoflurane up to 1.2% end-tidal concentration)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl-isoflurane anesthesia (infusion of fentanyl at 3 micrograms/kg/h and maintained with isoflurane up to 0.6% end-tidal concentration)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl-isoflurane anesthesia
Number of subjects: 42
Study: 11004367

Group type: EXPERIMENTAL
Intervention: Early feeding of low residue diets 6 hours postoperatively
Number of subjects: 139

Group type: COMPARATOR
Intervention: Traditional dietary management of clear liquids with normal bowel sounds, and regular diet with passage of flatus
Number of subjects: 139

Group type: COMPARATOR
Intervention: Late feeding group
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 139
Study: 8676624

Group type: EXPERIMENTAL
Intervention: 100 mg riluzole daily
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 50 mg riluzole daily
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 200 mg riluzole daily
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 1351736

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microgram kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 30770426

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) (±10,000 lux)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control light (±200 lux)
Number of subjects: 83
Study: 28474556

Group type: EXPERIMENTAL
Intervention: Ferritin levels up to about 80 ng/mL
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: %TS levels up to about 25%
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Ferritin levels up to about 100 ng/mL
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Ferritin levels over 100 ng/mL
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Modified normal ranges for ferritin from about 15 ng/mL up to about 80-100 ng/mL
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Modified normal ranges for %TS from about 15% up to about 25-55%
Number of subjects: 1277
Study: 25738178

Group type: EXPERIMENTAL
Intervention: Epithelial connective tissue graft (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Porcine collagen matrix (group B)
Number of subjects: 30
Study: 23614539

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1.0 g loading dose followed by another 1.0 g dose 3 hours later
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.9% saline placebo (control group)
Number of subjects: 98
Study: 21904221

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (HG) - 1000 mL of blood drawn and replaced with HES 130/0.4 (6%, Voluven) colloid.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG) - no blood drawn, hemodynamics stabilized using normal saline.
Number of subjects: 40
Study: 20032798

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg/day
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 18372722

Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP) in combination with dextroamphetamine (DEX)
Number of subjects: 0
Study: 15699539

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg/h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study: 12469755

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi-Purpose Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 Dual Cure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prime & Bond 2.1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgambond Plus
Number of subjects: 0
Study: 9674468

Group type: EXPERIMENTAL
Intervention: Nadolol (hydrophilic beta-blocker)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (lipophilic beta-blocker)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7831697

Group type: EXPERIMENTAL
Intervention: Department of Neurology
Number of subjects: 243

Group type: COMPARATOR
Intervention: Department of Medicine
Number of subjects: 243
Study: 2194380

Group type: COMPARATOR
Intervention: Monovalent CR influenza virus vaccine (type A H3N2, H1N1 and type B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bivalent CR influenza virus vaccine (type A H3N2 and H1N1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: CR influenza virus vaccine
Number of subjects: 57
Study: 382156

Group type: EXPERIMENTAL
Intervention: Intravenous domperidone (20 mg initially, followed by maintenance doses of 10 mg at 6 hourly intervals)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 31709895

Group type: EXPERIMENTAL
Intervention: Tunneled peripherally inserted central catheter
Number of subjects: 174

Group type: COMPARATOR
Intervention: Nontunneled peripherally inserted central catheter
Number of subjects: 174
Study: 31475465

Group type: EXPERIMENTAL
Intervention: Olive oil solution applied every 12 hours for 30 days
Number of subjects: 571

Group type: COMPARATOR
Intervention: Hyperoxygenated fatty acid compound applied every 12 hours for 30 days
Number of subjects: 571
Study: 29254111

Group type: EXPERIMENTAL
Intervention: FES therapy plus conventional rehabilitation program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 16
Study: 28162292

Group type: EXPERIMENTAL
Intervention: RRx-001 16.5mg/m2 IV 1x/week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regorafenib 160mg orally 21 of 28 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RRx-001 + irinotecan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regorafenib + irinotecan
Number of subjects: 26
Study: 23392087

Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI) annually (Control group)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: OHI and silver diamine fluoride (SDF) application annually
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: OHI and SDF application annually, plus oral health education (OHE) programme every 6 months
Number of subjects: 266
Study: 21816957

Group type: EXPERIMENTAL
Intervention: eCancerCare(Bladder)
Number of subjects: 12

Group type: COMPARATOR
Intervention: EMR
Number of subjects: 12
Study: 19139161

Group type: EXPERIMENTAL
Intervention: Fairness with intergroup competition present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrimination without intergroup competition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fairness without intergroup competition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrimination with intergroup competition
Number of subjects: 0
Study: 16868693

Group type: EXPERIMENTAL
Intervention: Mass mailing recruitment strategy
Number of subjects: 0
Study: 15101070

Group type: EXPERIMENTAL
Intervention: Crisis intervention model (additional therapy visits if needed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Follow-up only (no additional therapy visits)
Number of subjects: 30
Study: 11746070

Group type: EXPERIMENTAL
Intervention: Peer-mentored HIV risk-reduction program
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Nurse case-managed HIV risk-reduction program
Number of subjects: 633

Group type: COMPARATOR
Intervention: Standard care HIV risk-reduction program
Number of subjects: 633
Study: 9014950

Group type: COMPARATOR
Intervention: Single task performance (CVA groups)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combined computer tasks (CVA groups)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dual attentional task (Right CVA group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dual attentional task (Stroke subjects driving)
Number of subjects: 36
Study: 8323310

Group type: EXPERIMENTAL
Intervention: Cultured epidermal allografts
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nonadherent dressings
Number of subjects: 9
Study: 3553495

Group type: EXPERIMENTAL
Intervention: Beta-blocker (oxprenolol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium-entry blocker (nitrendipine)
Number of subjects: 60
Study: 29930257

Group type: EXPERIMENTAL
Intervention: Deep-learned 3D black-blood imaging
Number of subjects: 65

Group type: COMPARATOR
Intervention: Original black-blood imaging
Number of subjects: 65
Study: 28417279

Group type: EXPERIMENTAL
Intervention: Tacker
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyanoacrylate glue mesh fixation
Number of subjects: 66
Study: 26250761

Group type: EXPERIMENTAL
Intervention: DHS questionnaire
Number of subjects: 1189

Group type: COMPARATOR
Intervention: SSC questionnaire
Number of subjects: 1189
Study: 23414298

Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy once a week (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical application of heparinoid ointment twice daily and NB‐UVB phototherapy more than twice a week (group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical application of calcipotriol ointment twice daily and NB‐UVB phototherapy more than twice a week (group IV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 40
Study: 21347647

Group type: EXPERIMENTAL
Intervention: Tamoxifen (T) for 5 years
Number of subjects: 504

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen (CTT)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 504
Study: 19092335

Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no sevoflurane preconditioning)
Number of subjects: 64
Study: 17015900

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced full-dose PET/CT
Number of subjects: 47

Group type: COMPARATOR
Intervention: Unenhanced low-dose PET/CT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both PET/CT modalities
Number of subjects: 47
Study: 12643320

Group type: EXPERIMENTAL
Intervention: Danaparoid (10 IU/kg) administered subcutaneously twice daily for a mean of 16 days.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Danaparoid (2.6 IU/kg/h) administered intravenously for a mean of 17 days.
Number of subjects: 45
Study: 10836653

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 9115027

Group type: EXPERIMENTAL
Intervention: Misclassified male ever-smokers in cohort I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misclassified female ever-smokers in cohort I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Former smokers in cohort I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current smokers in cohort I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misclassified never-smokers in cohort I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort II results
Number of subjects: 0
Study: 8250362

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (n = 13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion (n = 10)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no transfusion, n = 12)
Number of subjects: 35
Study: 2944136

Group type: EXPERIMENTAL
Intervention: Inversion traction for two minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (standing for two minutes)
Number of subjects: 60
Study: 30362518

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus enoxaparin (40 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy only
Number of subjects: 0
Study: 28619985

Group type: EXPERIMENTAL
Intervention: Rhythm-and-music therapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Horse-riding therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Rhythm-and-music therapy and Horse-riding therapy
Number of subjects: 123
Study: 25863524

Group type: EXPERIMENTAL
Intervention: High intensity, low volume aerobic exercise (HI:LO, 70% VO2peak, 45 min, 3d/week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, high volume aerobic exercise (LO:HI, 50% VO2peak, 60 min, 4d/week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low to moderate intensity, low volume aerobic exercise (LO:LO, 50% VO2peak, 45 min, 3d/week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 48
Study: 23689475

Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention with higher population coverage (1 per 309 population)
Number of subjects: 19301

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19301
Study: 22032742

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS) at 20 Hz, 5 days a week for 4 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS)
Number of subjects: 54
Study: 19531521

Group type: EXPERIMENTAL
Intervention: Betamethasone (BM) 12 mg
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 17915499

Group type: EXPERIMENTAL
Intervention: Classroom-administered cognitive enhancement program (COGENT) throughout the school year
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement program (COGENT) for the first half of the year followed by pull‐out cognitive‐based reading enhancement program (PREP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No‐risk control group
Number of subjects: 45
Study: 15518095

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with dexamethasone 8 mg (group OD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 100
Study: 11529645

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Premenopausal patients and controls
Number of subjects: 31

Group type: COMPARATOR
Intervention: Postmenopausal patients and controls
Number of subjects: 31
Study: 9764038

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8628585

Group type: EXPERIMENTAL
Intervention: Applied relaxation training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined approach
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study: 3234635

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg three times daily for 3 days
Number of subjects: 15
Study: 1139193

Group type: EXPERIMENTAL
Intervention: Rimiterol (0.2, 0.1, and 0.05 mug kg‐minus1 min‐minus1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.1, 0.5, and 0.025 mug kg‐minus1 min‐minus1)
Number of subjects: 5
Study: 31902736

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 74
Study: 31496659

Group type: EXPERIMENTAL
Intervention: Tiopronin (15 mg/kg, 24 hrs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C (792 mg/kg, 24 hrs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resuscitation fluid volume requirement
Number of subjects: 0
Study: 28575389

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin + 250 mg relebactam
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin + 125 mg relebactam
Number of subjects: 298

Group type: COMPARATOR
Intervention: Imipenem/cilastatin alone
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All groups (including imipenem non-susceptible pathogens)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All groups (treatment-emergent adverse events)
Number of subjects: 298
Study: 25963104

Group type: EXPERIMENTAL
Intervention: Exercise trial (60 min of continuous moderate-high intensity treadmill running)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise trial
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 15
Study: 24197719

Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (n = 29)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention control group (n = 22)
Number of subjects: 51
Study: 21968856

Group type: EXPERIMENTAL
Intervention: Dietetic Intervention Treatment (DIT)
Number of subjects: 68
Study: 19489504

Group type: EXPERIMENTAL
Intervention: Hwato never and muscle stimulator
Number of subjects: 87

Group type: COMPARATOR
Intervention: G 6805 electronic stimulator
Number of subjects: 87
Study: 17406651

Group type: EXPERIMENTAL
Intervention: Measurement-based care (MBC) approach with citalopram as the first treatment step
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement-based care (MBC) approach
Number of subjects: 0
Study: 14729745

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h (n = 215)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Teicoplanin (n = 215)
Number of subjects: 430
Study: 11706534

Group type: EXPERIMENTAL
Intervention: Forward bending posture
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Elevated work posture
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Perceived exertion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 44
Study: 9204512

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 50
Study: 7967317

Group type: EXPERIMENTAL
Intervention: SM (streptomycin) twice weekly for 6 months in addition to INH and RFP for 9 months (S2 group)
Number of subjects: 212

Group type: COMPARATOR
Intervention: EB (ethambutol) for 6 months in addition to INH and RFP for 9 months (E group)
Number of subjects: 212
Study: 3337792

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 30
Study: 30821827

Group type: COMPARATOR
Intervention: 3 negative screens
Number of subjects: 22229

Group type: EXPERIMENTAL
Intervention: 2 positive screens with last negative or 2 negative screens with last positive
Number of subjects: 22229

Group type: EXPERIMENTAL
Intervention: 2 or more screens positive with last positive
Number of subjects: 22229

Group type: EXPERIMENTAL
Intervention: PLCO2012results (model including PLCOm2012 scores and screening results)
Number of subjects: 22229

Group type: EXPERIMENTAL
Intervention: Initial negative scans with elevated PLCOm2012 six-year risks of at least 2.6%
Number of subjects: 22229
Study: 28294373

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study: 25515276

Group type: EXPERIMENTAL
Intervention: Sleep Position Trainer (SPT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tennis Ball Technique (TBT)
Number of subjects: 55
Study: 23510568

Group type: EXPERIMENTAL
Intervention: Medium Light Roast (MLR) coffee
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medium Roast (MR) coffee
Number of subjects: 20
Study: 21158908

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus Melatonin 3 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus Melatonin 5 mg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 18469238

Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: White bread meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pasta meal
Number of subjects: 10
Study: 17880560

Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1-10 ng twice a week; n = 46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral sodium valproate (500 mg daily dose; n = 46)
Number of subjects: 92
Study: 14764889

Group type: EXPERIMENTAL
Intervention: mannitol‐LBG
Number of subjects: 60

Group type: COMPARATOR
Intervention: barium
Number of subjects: 60

Group type: COMPARATOR
Intervention: water
Number of subjects: 60
Study: 11723270

Group type: EXPERIMENTAL
Intervention: Brush-evoked allodynia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Capsaicin pain alone
Number of subjects: 8
Study: 9206908

Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography
Number of subjects: 100
Study: 7962392

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with endometriosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Peritoneal fluid from matched controls
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with mild endometriosis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with severe endometriosis
Number of subjects: 50
Study: 3631681

Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Brown recluse spider antivenom
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination therapy (dapsone and antivenom)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Erythromycin (given to all patients)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (historical data)
Number of subjects: 95
Study: 30680975

Group type: EXPERIMENTAL
Intervention: Triple therapy (LABA-LAMA-ICS) - vilanterol 25 µg/umeclidinium 62.5 µg/fluticasone furoate 100 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual therapy (LABA-ICS or LABA-LAMA)
Number of subjects: 0
Study: 28261978

Group type: EXPERIMENTAL
Intervention: EZ Shot 2™
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Procore®
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Expect™
Number of subjects: 109

Group type: COMPARATOR
Intervention: All needles
Number of subjects: 109
Study: 25635984

Group type: EXPERIMENTAL
Intervention: Obese group (120 subjects)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Non-obese group (142 subjects)
Number of subjects: 262